Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

被引：17
|
作者：
Schram, Alison M.
Ahnert, Jordi Rodon
Patel, Manish R.
Jauhari, Shekeab
Sachdev, Jasgit C.
Zhu, Viola Weijia
LoRusso, Patricia
Nguyen, Danny
Le, Xiuning
O'Connor, Matthew
Waters, Nigel
Cook, Carl
Witt, Karsten
Humphrey, Rachel W.
Janne, Pasi A.
Hamilton, Erika P.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[4] Florida Canc Specialists, Sarah Cannon Res Inst, Lake Mary, FL USA
[5] HonorHlth Res Inst, Scottsdale, AZ USA
[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
[7] Yale Univ, Sch Med, New Haven, CT USA
[8] Pacific Shores Med Grp, Long Beach, CA USA
[9] Black Diamond Therapeut Inc, New York, NY USA
[10] Black Diamond Therapeut Inc, Cambridge, MA USA
[11] Dana Farber Canc Inst, Boston, MA 02115 USA
[12] Tennessee Oncol LLC, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3086
引用
收藏
页数：2
相关论文
共 32 条
  • [21] A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors
    Ma, Fei
    Xu, Nong
    Tang, Huoling
    Zhou, Yuhong
    Wei, Ziping
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)
    Franklin, Anna
    Zecca, Marco
    Fagioli, Franca
    Luisi, Flavio Augusto
    Song, Gregory
    Suri, Ajit
    Leonard, E. Jane
    Locatelli, Franco
    BLOOD, 2018, 132
  • [23] Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.
    Lee, Dae Ho
    Roohullah, Aflah
    Cho, Byoung Chul
    Lemech, Charlotte Rose
    de Souza, Paul L.
    Millward, Michael
    Choi, Jun Young
    Park, Kyung Eui
    Lee, Minseon
    Kim, YeongMun
    Shin, Youngkee
    Han, Ji-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
    Dudek, M. A.
    Zaslona, Z.
    Blaszczyk, R.
    Grzybowski, M. M.
    Rejczak, T.
    Cabaj, A.
    Dera, P.
    Lisiecki, K.
    Iwanowski, P.
    Charitos, T.
    Fung, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S495 - S495
  • [25] Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Azad, Arun
    Gurney, Howard
    Underhill, Craig
    Horvath, Lisa
    Voskoboynik, Mark
    Li, Xinghai
    King, Ivan
    Shao, Lisa
    Dai, Yiyun
    Perabo, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [26] Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma
    Pal, Sumanta Kumar
    Tannir, Nizar M.
    Grell, Peter
    Gao, Xin
    Kotecha, Ritesh R.
    Picus, Joel
    De Braud, Filippo G.
    Takahashi, Shunji
    Wong, Alvin
    Suarez, Cristina
    Otero, Javier A.
    Kundamal, Nicole
    Yang, Xin
    Sharaby, Sherif
    Roy, Mike
    Barzaghi-Rinaudo, Patrizia
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors
    Solomon, Benjamin
    Gao, Bo
    Subbiah, Vivek
    Millward, Michael
    Rosen, Lee
    Desai, Jayesh
    Sbar, Eric I.
    Collins, Neal
    Thuy Hoang
    Song, Xi
    Shao, Wenlin
    Jaggi, Jaspreet
    Edris, Badreddin
    Ramachandran, Paraneedharan
    Luo, Lusong
    Friedlander, Michael
    CANCER RESEARCH, 2023, 83 (08)
  • [28] A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors
    Hamilton, Erika
    Zhang, Jian
    Liu, Liming
    Gao, Jie
    Shi, Rong
    Liu, Shengxue
    Wei, Gu
    Qiu, Yang
    Moore, Kathleen
    CANCER RESEARCH, 2023, 83 (08)
  • [29] A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors
    Cheng, Ying
    Lisberg, Aaron
    Lemech, Charlotte
    Abed, Afaf
    Chaudhry, Arvind
    Schmidt, Andrew
    Lu, Xin
    Zhu, Zhongyuan
    Gu, Wei
    Qiu, Yang
    Shi, Rong
    Zhang, Bin
    CANCER RESEARCH, 2024, 84 (07)
  • [30] A phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced/metastatic solid tumors
    Lisberg, Aaron
    Lu, Shun
    Starodub, Alexander
    Amin, Harshad
    Rotow, Julia
    Wu, Lin
    Spira, Alexander
    Hamilton, Erika
    Shen, Weidi
    Liu, Liming
    Zhu, Zhongyuan
    Gu, Wei
    Qiu, Yang
    Shi, Rong
    Liu, Shengxue
    CANCER RESEARCH, 2024, 84 (07)
1234